When government regulates the vast diversity and complexity of markets and other institutions, it can never plan for every unexpected turn of events. Yet during such an emergency, rules that a regulated sector could otherwise live with may no longer make sense. Then regulation becomes the enemy of resilience.
COVID-19 exposed some of these weaknesses in a dramatic way. In quieter times, Congress and the Food and Drug Administration (FDA) had asserted regulatory authority over medical testing and medical devices, the latter defined broadly to include not only implanted pacemakers and radiation units but a host of simple products such as bedpans, tongue depressors, surgical masks, and glass pipettes.